SEER vs. AKYA, BNGO, PRE, RPID, NAUT, SGMT, CYBN, RAPT, VIGL, and TELA
Should you be buying Seer stock or one of its competitors? The main competitors of Seer include Akoya Biosciences (AKYA), Bionano Genomics (BNGO), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Nautilus Biotechnology (NAUT), Sagimet Biosciences (SGMT), Cybin (CYBN), RAPT Therapeutics (RAPT), Vigil Neuroscience (VIGL), and TELA Bio (TELA). These companies are all part of the "medical" sector.
Akoya Biosciences (NASDAQ:AKYA) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.
79.4% of Akoya Biosciences shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 7.3% of Akoya Biosciences shares are held by insiders. Comparatively, 15.0% of Seer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Akoya Biosciences has higher revenue and earnings than Seer. Akoya Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences has a net margin of -72.68% compared to Akoya Biosciences' net margin of -529.52%. Akoya Biosciences' return on equity of -20.69% beat Seer's return on equity.
Akoya Biosciences has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.
Akoya Biosciences received 25 more outperform votes than Seer when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
In the previous week, Akoya Biosciences had 10 more articles in the media than Seer. MarketBeat recorded 15 mentions for Akoya Biosciences and 5 mentions for Seer. Akoya Biosciences' average media sentiment score of 0.07 beat Seer's score of -0.27 indicating that Seer is being referred to more favorably in the news media.
Akoya Biosciences currently has a consensus target price of $7.79, indicating a potential upside of 168.47%. Seer has a consensus target price of $7.00, indicating a potential upside of 230.19%. Given Akoya Biosciences' higher probable upside, analysts clearly believe Seer is more favorable than Akoya Biosciences.
Summary
Akoya Biosciences beats Seer on 9 of the 17 factors compared between the two stocks.
Get Seer News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
